BELLSHILL, SCOTLAND, 26 March 2014: Link Technologies Ltd (www.linktech.co.uk), an ISO 9001:2008 certified specialist oligonucleotide reagent manufacturer, has expanded its range of lipophilic modifiers for the effective delivery of oligonucleotides into cells. As oligos continue to be of interest in drug discovery, offering exciting potential as therapeutic agents, there is an increasing demand for improved oligo delivery techniques. Link’s proven collection of lipophilic oligo modification reagents, which include cholesterol and tocopherol modifiers, now also includes 5’-Palmitate-C6-CE Phosphoramidite. As a derivative of palmitic acid, a physiologically common fatty acid, the new palmitate modifier is the first palmitate phosphoramidite available commercially, and provides scientists with an ideal approach to improve the cellular uptake and utilisation of oligos.
In the cell, palmitic acid is known to conjugate to proteins via cysteine residues and, in doing so, is believed to aid the movement of proteins between intracellular compartments. It is also known that improved...
Commenting on the new addition to Link’s breakthrough range of lipophilic modifiers, Catherine McKeen, Head of Technology Commercialisation, explained: “Labelling oligos with hydrophobic compounds has proved a successful technique for enhancing cell delivery. We are continuing to develop our range of reagents for use in this field so that we can always offer our customers the most effective methods for oligo delivery. Palmitate, due to its proven ability to improve oligonucleotide delivery, is a natural choice for addition to our delivery agent portfolio.”
Available from small milligramme quantities to larger bulk scale, 5’-Palmitate-C6-CE Phosphoramidite can be ordered online from the Link website www.linktech.co.uk. Scientists can also access protocol information online, detailing the use of 5’-Palmitate in oligonucleotide synthesis, for confident incorporation and application of this lipophilic modifier.